The global cell and gene therapy manufacturing market size surpassed USD 9.16 billion in 2023 and is estimated to increase from USD 11.60 billion in 2024 to approximately USD 122.86 billion by 2034. It is projected to grow at a CAGR of 26.62% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell and Gene Therapy Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell and Gene Therapy Manufacturing Market, by Therapy, 2024-2033
8.1.1. Cell Therapy Manufacturing
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Gene Therapy Manufacturing
8.1.2.1. Market Revenue and Forecast (2021-2033)
9.1. Cell and Gene Therapy Manufacturing Market, by Scale, 2024-2033
9.1.1. Pre-commercial/ R&D Scale Manufacturing
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Commercial Scale Manufacturing
9.1.2.1. Market Revenue and Forecast (2021-2033)
10.1. Cell and Gene Therapy Manufacturing Market, by Mode, 2024-2033
10.1.1. Contract Manufacturing
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. In-house Manufacturing
10.1.2.1. Market Revenue and Forecast (2021-2033)
11.1. Cell and Gene Therapy Manufacturing Market, by Workflow, 2024-2033
11.1.1. Cell Processing
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Cell Banking
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Process Development
11.1.3.1. Market Revenue and Forecast (2021-2033)
11.1.4. Fill & Finish Operations
11.1.4.1. Market Revenue and Forecast (2021-2033)
11.1.5. Analytical & Quality Testing
11.1.5.1. Market Revenue and Forecast (2021-2033)
11.1.6. Raw Material Testing
11.1.6.1. Market Revenue and Forecast (2021-2033)
11.1.7. Vector Production
11.1.7.1. Market Revenue and Forecast (2021-2033)
11.1.8. Others
11.1.8.1. Market Revenue and Forecast (2021-2033)
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.1.2. Market Revenue and Forecast, by Scale (2021-2033)
12.1.3. Market Revenue and Forecast, by Mode (2021-2033)
12.1.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Scale (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Mode (2021-2033)
12.1.5.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Scale (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Mode (2021-2033)
12.1.6.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.2.2. Market Revenue and Forecast, by Scale (2021-2033)
12.2.3. Market Revenue and Forecast, by Mode (2021-2033)
12.2.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Scale (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Mode (2021-2033)
12.2.5.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Scale (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Mode (2021-2033)
12.2.6.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Scale (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Mode (2021-2033)
12.2.7.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Scale (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Mode (2021-2033)
12.2.8.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.3.2. Market Revenue and Forecast, by Scale (2021-2033)
12.3.3. Market Revenue and Forecast, by Mode (2021-2033)
12.3.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Scale (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Mode (2021-2033)
12.3.5.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Scale (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Mode (2021-2033)
12.3.6.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Scale (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Mode (2021-2033)
12.3.7.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Scale (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Mode (2021-2033)
12.3.8.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.4.2. Market Revenue and Forecast, by Scale (2021-2033)
12.4.3. Market Revenue and Forecast, by Mode (2021-2033)
12.4.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Scale (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Mode (2021-2033)
12.4.5.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Scale (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Mode (2021-2033)
12.4.6.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Scale (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Mode (2021-2033)
12.4.7.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Scale (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Mode (2021-2033)
12.4.8.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.5.2. Market Revenue and Forecast, by Scale (2021-2033)
12.5.3. Market Revenue and Forecast, by Mode (2021-2033)
12.5.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Scale (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Mode (2021-2033)
12.5.5.4. Market Revenue and Forecast, by Workflow (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Scale (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Mode (2021-2033)
12.5.6.4. Market Revenue and Forecast, by Workflow (2021-2033)
13.1. Wuxi Advanced Therapies
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Merck KGaA
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Novartis AG
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffmann-La Roche Ltd
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Thermo Fischer Scientific
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Miltenyi Biotec
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Takara Bio Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Bluebird Bio Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Hitachi Chemical Co., Ltd.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Cellular Therapeutics
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample